Treatment Options for Sickle Cell Disease-Reference-Cited by-同舟云学术

Treatment Options for Sickle Cell Disease

Published:2018-06 Issue:3 Volume:65 Page:427-443
ISSN:0031-3955
Container-title:Pediatric Clinics of North America
language:en
Short-container-title:Pediatric Clinics of North America

Author:

Meier Emily Riehm

Funder

Pfizer

Publisher

Elsevier BV

Subject

Pediatrics, Perinatology, and Child Health

Reference84 articles.

1. Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia;Herrick;JAMA,2014

2. Mortality in sickle cell disease. Life expectancy and risk factors for early death;Platt;N Engl J Med,1994

3. Mortality rates and age at death from sickle cell disease: U.S., 1979-2005;Lanzkron;Public Health Rep,2013

4. Erythrocyte plasma membrane-bound ERK1/2 activation promotes ICAM-4-mediated sickle red cell adhesion to endothelium;Zennadi;Blood,2012

5. Endothelial nitric oxide synthase (-786T>C) and Endothelin-1 (5665G>T) gene polymorphisms as vascular dysfunction risk factors in sickle cell anemia;Vilas-Boas;Gene Regul Syst Bio,2016

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revolutionising healing: Gene Editing's breakthrough against sickle cell disease;Blood Reviews;2024-05

2. Sickle Cell Disease in Brazil: Current Management;Hemoglobin;2024-04-25

3. Computational identification of potential modulators of heme-regulated inhibitor (HRI) for pharmacological intervention against sickle cell disease;Journal of Biomolecular Structure and Dynamics;2024-03-31

4. Disease-Modifying Therapies for Sickle Cell Disease—An Overview;Pediatric Annals;2024-02

5. Computational identification of potential modulators of heme-regulated inhibitor (HRI) for pharmacological intervention against sickle cell disease;2023-12-15